1990
Conception delay after oral contraceptive use: the effect of estrogen dose**Supported by grant HD 11357 and HD 16282 from the National Institutes for Child Health and Human Development and by grant DA 05484 from the National Institute for Drug Abuse, Bethesda, Maryland.
Bracken M, Hellenbrand K, Holford T. Conception delay after oral contraceptive use: the effect of estrogen dose**Supported by grant HD 11357 and HD 16282 from the National Institutes for Child Health and Human Development and by grant DA 05484 from the National Institute for Drug Abuse, Bethesda, Maryland. Fertility And Sterility 1990, 53: 21-27. PMID: 2295345, DOI: 10.1016/s0015-0282(16)53210-5.Peer-Reviewed Original ResearchConceptsOral contraceptive useContraceptive useFormer oral contraceptive usersConception delayFormer OC usersLower estrogen dosesOral contraceptive usersEffects of estrogenNational InstituteMethod of contraceptionEstrogen doseOC discontinuationEstrogen dosesOral contraceptionOC usersContraceptive usersChild healthProbability of conceptionHigh dosesDrug abuseMean timeDiscontinuationSignificant delaySignificant reductionEstrogen
1984
Exogenous hormone use and fibrocystic breast disease by histopathologic component
Berkowitz G, Kelsey J, Livolsi V, Merino M, Holford T, Hildreth N, Ort S, O'Connor T, White C. Exogenous hormone use and fibrocystic breast disease by histopathologic component. International Journal Of Cancer 1984, 34: 443-449. PMID: 6490201, DOI: 10.1002/ijc.2910340403.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseEstrogen replacement therapyBreast diseaseGross cystsReplacement therapyHospital-based case-control studyExogenous hormone useOral contraceptive usePost-menopausal womenCase-control studyPostmenopausal womenPremenopausal womenHormone useOral contraceptivesEpithelial atypiaControl womenPapillary hyperplasiaBiopsy specimensFibrocystic lesionsSurgical conditionsContraceptive useHistopathologic componentsWomenIncreased occurrenceDiseaseORAL CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PRE- AND POSTMENOPAUSAL WOMEN1
BERKOWITZ G, KELSEY J, LIVOLSI V, HOLFORD T, MERINO M, ORT S, O'CONNOR T, GOLDENBERG I, WHITE C. ORAL CONTRACEPTIVE USE AND FIBROCYSTIC BREAST DISEASE AMONG PRE- AND POSTMENOPAUSAL WOMEN1. American Journal Of Epidemiology 1984, 120: 87-96. PMID: 6741927, DOI: 10.1093/oxfordjournals.aje.a113878.Peer-Reviewed Original ResearchConceptsFibrocystic breast diseaseOral contraceptive useBreast diseaseOral contraceptivesContraceptive useHospital-based case-control studyOral contraceptive exposureGeneral surgical serviceCase-control studyLong-term useContraceptive exposurePostmenopausal women1Postmenopausal womenPremenopausal womenCystic diseaseStudy groupSurgical servicesDecreased frequencyPast usersDiseaseIncreased occurrenceWomenContraceptivesNegative associationAssociation
1983
Oral Contraceptive Use and Fibrocystic Breast Disease With Special Reference to Its Histopathology23
Pastides H, Kelsey J, LiVolsi V, Holford T, Fischer D, Goldenberg I. Oral Contraceptive Use and Fibrocystic Breast Disease With Special Reference to Its Histopathology23. Journal Of The National Cancer Institute 1983, 71: 5-9. PMID: 6575209, DOI: 10.1093/jnci/71.1.5.Peer-Reviewed Original ResearchConceptsOral contraceptive useFibrocystic breast diseaseOral contraceptivesContraceptive useBiopsy specimensBreast diseaseHospital-based case-control studyCase-control studyHigh atypiaEpithelial atypiaGross cystsHistopathologic characteristicsFibrocystic diseaseAtypiaContraceptivesDiseaseMicroscopic cystsCystsNew HavenSimilar patternPapillomatosisHistopathologySpecial referenceCasesControl
1979
Fibroadenoma in oral contraceptive users. A histopathologic evaluation of epithelial atypia
Livolsi V, Stadel B, Kelsey J, Holford T. Fibroadenoma in oral contraceptive users. A histopathologic evaluation of epithelial atypia. Cancer 1979, 44: 1778-1781. PMID: 498048, DOI: 10.1002/1097-0142(197911)44:5<1778::aid-cncr2820440535>3.0.co;2-y.Peer-Reviewed Original ResearchConceptsEpithelial atypiaLong-term usersOral contraceptivesOral contraceptive useOral contraceptive usersFibrocystic diseaseHistopathologic evaluationBreast diseaseContraceptive usersCytologic atypiaContraceptive useEpithelial componentAtypiaEpidemiological investigationsFibroadenomaDiseaseContraceptives
1978
Role of Oral Contraception in Congenital Malformations of Offspring
BRACKEN M, HOLFORD T, WHITE C, KELSEY J. Role of Oral Contraception in Congenital Malformations of Offspring. International Journal Of Epidemiology 1978, 7: 309-317. PMID: 744667, DOI: 10.1093/ije/7.4.309.Peer-Reviewed Original ResearchConceptsOral contraceptivesCongenital malformationsHealthy control infantsOral contraceptive useCase-control studyTime of conceptionOccurrence of malformationsControl infantsMaternal exposureOral contraceptionContraceptive useMalformed infantsSpecific estrogenSpecific diagnosisControl studyPregnancyMalformationsContraceptivesCardiovascular defectsInfantsExposureWomenProgestogensOffspringEstrogen